Quotient Sciences

Quotient Sciences accelerates drug development by offering end-to-end CDMO and CRO services, from formulation and preclinical studies through Phase I-II clinical manufacturing and commercial production. Leveraging state-of-the-art facilities in the U.S. and U.K., the company delivers high-potency handling, real-time adaptive manufacturing, and pediatric formulation expertise to reduce time-to-market and cost. Its integrated, data-driven approach—combining pharmacokinetics, bioanalysis, modelling and simulation—ensures seamless translation of molecules into viable therapies. A culture of teamwork, continuous improvement and customer-centric service empowers over 1,300 professionals to innovate and mentor one another. Quotient Sciences stands out by turning ideas into cures quickly, making it an attractive workplace for professionals who want to impact global health.